APA (7th ed.) Citation

Jacobson, C. A., Chavez, J. C., Sehgal, A. R., William, B. M., Munoz, J., Salles, G., . . . Neelapu, S. S. (2020). IBCL-124: Interim Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL). Clinical lymphoma, myeloma and leukemia, 20, S278. https://doi.org/10.1016/S2152-2650(20)30898-3

Chicago Style (17th ed.) Citation

Jacobson, Caron A., et al. "IBCL-124: Interim Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R INHL)." Clinical Lymphoma, Myeloma and Leukemia 20 (2020): S278. https://doi.org/10.1016/S2152-2650(20)30898-3.

MLA (9th ed.) Citation

Jacobson, Caron A., et al. "IBCL-124: Interim Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R INHL)." Clinical Lymphoma, Myeloma and Leukemia, vol. 20, 2020, p. S278, https://doi.org/10.1016/S2152-2650(20)30898-3.